搜尋結果
Wegovy maker Novo Nordisk down 4%, heads for worst day since October
CNBC· 3 小時前Novo Nordisk, which also makes diabetes treatment Ozempic, said the rise in sales had offset
Novo Slides as Amgen Fuels Obesity Drug Competition Fears
Bloomberg· 7 小時前Have a confidential tip for our reporters? Novo Nordisk A/S shares fell as
Futures rise on Apple, Amgen boost; jobs data on tap
Reuters· 6 小時前, opens new tab jumped 5.8%, outpacing other megacap stocks in premarket trading after the iPho ...
Rescheduling Marijuana Won’t Reduce Regulatory Confusion On Drug’s Use
Forbes· 1 日前Earlier this year, USA Today reported that a federal scientific review conducted by scientists ...
Bausch Health investors are left in a holding pattern as 2 major overhangs remain unresolved
CNBC· 22 小時前Bausch Health Companies on Tuesday morning reported first-quarter top- and bottom-line misses — ...
This Startup’s AI Designs Enzymes That Can Eat Plastic Waste
Forbes· 11 小時前It’s about to become food for an enzyme designed with the help of artificial intelligence, made ...
Amgen shares jump after teasing 'encouraging' weight loss data
Reuters· 6 小時前U.S. drugmaker Amgen's shares jumped 13% to $316.26 premarket on Friday as the company ... ...
Healthy Returns: Sales of Humira are plunging, but AbbVie has two promising successors
CNBC· 2 日前Sales of AbbVie's Humira are plummeting as the once-top-selling drug fights competition ... ...
The Ozempic Effect: How a Weight Loss Wonder Drug Gobbled Up an Entire Economy
Bloomberg· 3 日前There is no escaping Ozempic and Wegovy. The diabetes and obesity drugs are a global ... ...
GSK knew about Zantac cancer risk, attorneys tell jury in first trial
Reuters· 21 小時前U.S. attorneys for a woman who claims her colon cancer was caused by the now discontinued ... ...